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Recent data suggest that recombinant human erythropoietin (rhEPO) modulates tumour growth and therapy response. The purpose
of the present study was to examine the modulation of radiotherapy (RT) effects on tumour microvessels by rhEPO in a rat
colorectal cancer model. Before and after 5 5Gy of RT, dynamic contrast-enhanced -magnetic resonance imaging was performed
and endothelial permeability surface product (PS), plasma flow (F), and blood volume (V) were modelled. Imaging was combined with
pO2 measurements, analysis of microvessel density, microvessel diameter, microvessel fractal dimension, and expression of vascular
endothelial growth factor (VEGF), hypoxia-inducible factor-1 a (HIF-1a), Bax, and Bcl-2. We found that RT significantly reduced PS
and V in control rats, but not in rhEPO-treated rats, whereas F was unaffected by RT. Oxygenation was significantly better in rhEPO-
treated animals, and RT induced a heterogeneous reoxygenation in both groups. Microvessel diameter was significantly larger in
rhEPO animals, whereas VEGF expression was significantly lower in the rhEPO group. No differences were observed in HIF-1a, Bax,
or Bcl-2 expression. We conclude that rhEPO results in spatially heterogeneous modulation of RT effects on tumour microvessels.
Direct effects of rhEPO on neoplastic endothelium are likely to explain these findings in addition to indirect effects induced by
increased oxygenation.
British Journal of Cancer (2007) 96, 692–700. doi:10.1038/sj.bjc.6603568 www.bjcancer.com
Published online 13 February 2007
& 2007 Cancer Research UK
Keywords: erythropoietin; radiothkerapy; oxygenation; colorectal; microcirculation
                                                                                                       
Anaemia commonly occurs in colorectal cancer patients especially
if they are treated with neoadjuvant radiotherapy (RT) or
chemotherapy. Anaemia not only adversely affects the clinical
condition of these patients, but also contributes to the develop-
ment of tumour hypoxia, recognised as a major negative
determinant of sensitivity to RT, chemoradiotherapy, and certain
chemotherapeutic agents (Harrison and Blackwell, 2004; van
Halteren et al, 2004).
Recent clinical studies have shown that administration of
recombinant human erythropoietin (rhEPO, epoetin alfa) increases
haemoglobin levels and improves quality of life in patients with
cancer-related anaemia (Littlewood et al, 2001). Over the last
decade, it has become clear that the action or rhEPO extends into
a wide range of cellular mechanisms involved in stem cell
development, maintenance of cellular integrity, and physiological
angiogenesis (Maiese et al, 2005). The demonstration of the
erythropoietin (EPO) receptor in various neoplastic tissues and the
observation in a recent clinical trial that mortality was higher in
nonanaemic rhEPO-treated breast cancer patients highlighted the
possible effects of rhEPO on tumour growth and angiogenesis
(Leyland-Jones, 2003). Preclinical studies investigating the role of
EPO and EPO–EPO receptor signalling on tumour growth and
angiogenesis have yielded contradictory results. Yasuda et al
(2003) noted the inhibition of angiogenesis and tumour cell
survival in stomach and melanoma xenografts following blockade
of EPO signalling. The results of Hardee et al (2005), however,
suggested that administration of rhEPO did not affect angiogenesis
or tumour growth in human colon and head and neck xenografts.
The importance of tumour oxygenation for RT response is well
established, and there has been considerable interest in modulat-
ing tumour oxygenation and RT response by rhEPO administra-
tion. Experimentally, exogenous rhEPO has been shown to
improve or restore radioresponsiveness in both anaemic and
nonanaemic animals (Thews et al, 1998; Stuben et al, 2003; Pinel
et al, 2004). Interestingly, darbepoetin alfa, an EPO analogue with a
longer half-life, did not enhance radioresponsiveness in a rat
mammary adenocarcinoma model (Kirkpatrick et al, 2006).
The exact mechanism by which rhEPO exerts its effects on
tumour oxygenation is at present unclear. Indeed, recent data
suggest that this effect may be independent of changes in
haemoglobin and mediated by changes in vascular endothelial
growth factor (VEGF) expression and microvessel morphology
(Blackwell et al, 2003; Tovari et al, 2005).
We aimed to further characterise the effects of rhEPO on
microvascular morphology and function in non-anaemic rats
using a novel imaging methodology. We previously used dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI) with a
macromolecular contrast agent (CA) to demonstrate a significantly
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sdecreased neovascular leakage after fractionated RT in a rat
colorectal cancer model (Ceelen et al, 2006). Dynamic contrast-
enhanced magnetic resonance imaging allows noninvasive in vivo
study of microvascular properties of a complete tumour, thereby
taking into account the important spatial heterogeneity of solid
tumours with zones of well perfused tissue, as well as hypoxic or
necrotic areas (Hylton, 2006). Here, we studied the effects of
rhEPO on RT-induced microenvironmental changes in a rat
colorectal cancer model and correlated noninvasively obtained
data with invasive oxygenation and flow measurements, micro-
vessel density, complexity and diameter, and expression of
hypoxia-regulated and apoptosis markers.
MATERIALS AND METHODS
The experimental protocol was approved by the Animal Experimenta-
tion Ethical Committee of the Ghent University, Ghent, Belgium.
Animal and tumour model
Male Wag/Rij rats were bought from Harlan (Horst, The Nether-
lands). The CC531 cell line is a 1,2-dimethylhydrazine-induced,
moderately differentiated, and weakly immunogenic colon adeno-
carcinoma, syngeneic with WAG/Rij rats. This cell line is well
studied and has been proven to provide a tumour–host model
similar to human colorectal carcinogenesis (Hagenaars et al, 2000).
Cells were grown in plastic culture flasks in RPMI 1640 medium,
buffered with HEPES (20mM) (Invitrogen Corporation, Gibco,
Ghent, Belgium) additionally supplemented with 10% fetal calf
serum, 4mML -glutamine, 50Uml
 1 penicillin, and 50mgml
 1
streptomycin at 371C in a humidified atmosphere with 5% CO2 in
air. The cells were transferred at 95% confluency. Two million cells
suspended in 0.2ml of saline were injected subcutaneously (s.c.)
in the proximal hind leg. Tumours reached a size of 0.5–1cm after
a period of 4 weeks. Once a tumour growth of minimally 8mm
diameter was observed, a jugular vein catheter was inserted and
tunnelled to the interscapular region. To maintain catheter patency,
continuous infusion at 0.5ml saline per hour was administered
with a cage-mounted swivel and a flexible metal tether system (Uno
BV, Didam, The Netherlands) allowing the animal full mobility.
Experimental therapy
Recombinant human EPO has been shown to bind to the rodent
EPO receptor (Okano et al, 1993). Animals were randomly divided
into two groups: a control group (n¼11) and an rhEPO group
(n¼15) receiving rhEPO (Eprex
s, Janssen Cilag, Beerse, Belgium)
at a dose of 3 0.1ml (286IU) s.c. per week. The dosage was based
on a dose-finding study during which five or eight rhEPO
administrations weekly resulted in an excessive haematocrit rise
and important mortality (data not shown).
Rats were longitudinally studied during 3 weeks using the
following timeframe: start of rhEPO administration (day 1); first
DCE-MRI, oxygenation and flow measurement (day 8); fractio-
nated RT 5 5Gy (day 13–17); second DCE-MRI, oxygenation
and flow measurement, and killing by anaesthesia overdose and
excision of tumours for histology (all on day 22).
Radiotherapy
Rats were not sedated and the tumour-bearing hind leg was
immobilised using a Plexiglass holder, as described previously
(Ceelen et al, 2001; El-Malt et al, 2001). Briefly, rats were placed in
a purpose-built Plexiglass holder in prone position. The hind legs
were pulled through an opening in the holder and immobilised.
Before each fraction, a radiation field was simulated encompassing
the tumour with a margin of 1.5cm. Photon irradiation was
performed with a 5MV linear accelerator (Elekta, Crawley, UK).
Five fractions of 5Gy (total dose 25Gy) were delivered on five
consecutive days. As the tumours were inoculated s.c., they were
covered with tissue-equivalent silicone bolus of 1cm to prevent the
build-up effect under the skin. One single direct field at a fixed source-
skin distance of 100cm was used. The dose was calculated to the
midpoint of the tumours according to their volume in each individual
animal, as obtained during simulation. Dynamic contrast-enhanced
magnetic resonance imaging and oxygenation measurements were
performed 5 days before and 5 days after the completion of RT.
Magnetic resonance imaging
The principle of DCE-MRI consists of serial measurements of
signal intensity changes in both tumour tissue and a feeding artery
after bolus injection of a paramagnetic CA. Depending on the
physical properties of the CA and the leakiness of the microvessel
wall, a fraction of the CA will reach the interstitial space of the
tumour, where an increase in signal intensity over time will be
observed. After translation of signal intensity changes to CA
concentration values, pharmacokinetic modelling allows calcula-
tion of physiological properties such as microvessel permeability
and tumour blood volume.
Dynamic contrast studies were performed with P792, a new
monogadolinated rapid clearance MRI blood-pool CA, which is
cleared by renal elimination. The molecular weight of the
compound is 6.47kDa, but the mean diameter of P792 is 50.5A ˚
and the T1 relaxivity of this agent is 29mM
 1s
 1 at 60MHz (Port
et al, 2001a). The apparent hydrodynamic volume of P792 is 125
times greater than that of Gd-DOTA (gadoterate meglumine,
Dotarem) and as a result of this high molecular volume, P792 is
characterised by a limited diffusion across the normal endothelium
and therefore ideally suited to study hyperpermeable neoplastic
vessels (Port et al, 2001b). Experimentally, P792 has been used to
study permeability effects of anti-angiogenesis therapy in a
prostate cancer model (Pradel et al, 2003). We have previously
demonstrated that P792 selectively enhances tumour tissue in this
colorectal cancer model (Ceelen et al, 2006).
T1-weighted DCE-MRI was performed on a Siemens Magnetom
Symphony
s 1.5T scanner (Siemens AG, Erlangen, Germany).
Animals were sedated with 0.2–0.4ml of medetomidine
(Domitor
s, Novartis Animal Health, Basel, Switzerland). Imaging
comprised a single axial slice that was positioned through both
lower limbs and the centre of the tumour. Before the contrast
series, T1 zero time maps were constructed from two spin echo
sequences with different repetition times (TR 1000 and 318ms,
respectively). Details of this sequence were as follows: slice
thickness 3mm, field of view (FOV) 140 88, matrix size
256 160, echo time (TE) 20ms, and flip angle 901. Dynamic
imaging was performed with a 4-antenna wrist coil (diameter 10cm)
using an inversion recovery TurboFLASH sequence. Details of the
pulse sequence were as follows: temporal resolution 1.1s (i.e. TR
1100ms), FOV 140 88, matrix size 256 160, slice thickness 5mm,
TE 4.08ms, inversion time 560ms, and flip angle 121.Ab o l u so f0 . 3–
0.4ml of P792 was manually injected as fast as possible (approxi-
mately 1mls
 1) through a central venous line after the fourth scan. A
total of 500 images was obtained for a total scan time of 550s.
Tracer kinetic modelling
Pixel-by-pixel pharmacokinetic modelling of DCE-MRI data was
performed with the research mode of a dedicated software package
(MIStar
s, Apollo Medical Imaging, Melbourne, Australia). Extrac-
tion of both microvascular permeability and flow data was based
on the tissue homogeneity (TH) model of capillary exchange
originally described by Johnson and Wilson (1966) and later
adapted for the study of cerebral flow by St Lawrence and Lee
(1998); . This model (Figure 1) consists of a plasma space, in which
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sthe CA concentration is a function of both time and distance along
the capillary unit, and an extracellular extravascular space (EES)
assumed to be homogenously mixed (i.e. a compartment). Leakage
of CA takes place between the vascular space and EES through a
semipermeable membrane characterised by a permeability surface
product (PS). As P792 does not enter the intracellular compart-
ment, the sum of the fractional plasma volume (Vp) and fractional
extracellular volume (Ve) reached by the CA equals 100%, that is,
VpþVe¼1.
When the assumption is made that changes in EES concentra-
tion per unit time are negligible compared with changes in plasma
concentration, an adiabatic approximation to the TH model can be
derived, which has been used in modelling of DCE-MRI CA
kinetics applied to tumour microvasculature (St Lawrence and Lee,
1998; Henderson et al, 2000).
The adiabatic approximation to tissue homogeneity (AATH)
model is given by superposition of the arterial input function (AIF)
with a time-varying residue function:
CeðtÞ¼FpCaðtÞ RðtÞ
where Ce (mM) is the CA concentration in the EES, Fp (unitless) is
the plasma flow, R denotes the residue function, and # is the
convolution operator.
The time course of CA arrival is divided in a vascular phase
(tot, with tau as the transit time through a capillary) and a tissue
phase (t4t). Depending on the time interval, the residue function
will encompass a vascular and a tissue component:
RðtÞ¼10 Xtot
RðtÞ¼Ee
 Ktrans
ve ðt tÞ tXt
with E the extraction ratio from plasma space to EES, K
trans the
endothelial transfer constant (min
 1), ve the fraction of the EES
available as leakage space (unitless), and t is the mean capillary
transit time (s).
The tissue CA concentration can therefore be modelled as
Ce ¼ Fp
Z t
0
Caðt   t0Þdt0 þ Ktrans
Z t
t
Caðt0Þe
 Ktrans
ve ðt t0 tÞdt0
In each animal, the pixel containing the AIF curve was selected
in the femoral artery feeding the tumour-bearing limb. A region
of interest (ROI) was drawn encompassing the outer vascular rim
of each tumour. Within this ROI, a pixel by pixel curve-fitting
routine based on the Levenberg–Marquardt minimisation method
was performed, generating parametric maps (Figure 2) of the
following parameters: Fp, PS, and the fractional plasma volume Vp,
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Figure 1 Illustration of the St Lawrence and Lee tissue homogeneity model applied to dynamic MRI data. (A) Two-compartment model used for kinetic
modelling. Following injection, CA enters the tissue capillary unit (length  ) and distributes between the vascular space and the EES through a
semipermeable vessel wall characterised by a permeability surface product PS. Measurement of the temporal changes in CA concentration (calculated from
changes in MRI signal intensity) in both the vascular space and the EES allows to calculate the F, Vp, and PS. (B, C) Examples of contrast enhancement curves
(500 images with 1.1s temporal resolution) observed in regions of interest selected in the tumour rim (red), tumour core (blue), and normal muscle. Normal
microvessels do not leak the macromolecular contrast agent. The colorectal cancer is grown subcutaneously in the left lower limb.
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Figure 2 Immunoreactivity of the erythropoietin receptor. (A) Representative immunohistochemistry showing both cytoplasmatic and membrane
staining of tumour cells and endothelial cells (arrow). Bar, 25mm. (B) Comparison of EPO-R immunoreactivity scores in the tumour rim and core of both
control and rhEPO-treated animals. Columns, mean; bars, s.e.; *Po0.001 vs the tumour core.
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scalculated as Fp MTT. Numerical parameter values for each pixel
were exported to a spreadsheet for statistical analysis.
Tissue pO2 and flow measurements
Tissue oxygenation and laser Doppler flow (LDF) were measured
with a fibreoptic probe combining fluorescence quenching with
laser Doppler flowmetry (OxyLite
s and OxyFlo
s, Oxford Optro-
nix, Oxford, UK) (Blackwell et al, 2003; Brurberg et al, 2004). A
precalibrated fibreoptic probe was inserted 5mm deep into the
tumour using a Seldinger technique; the probe was then withdrawn
in 40 steps of 100mm each over a total distance of 4mm using a
micromanipulator (model MN151, Narishige International Ltd,
London, UK). After each micromanipulator movement, measure-
ments were started as soon as a stable reading was obtained. Tissue
pO2 was sampled every 2s. Over this 4mm trajectory, oxygenation
and LDF values were recorded separately for the tumour core
(central 1–2mm) and peripheral angiogenic rim (outer 1mm).
Tissue pO2 was expressed in mmHg, whereas LDF was expressed in
arbitrary units (a.u.).
Immunohistochemistry
Paraffin-embedded tissue samples were used for immunohisto-
chemistry with the following antibodies: anti-EPO receptor (M-20)
(sc-697, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA),
anti-Bcl-2 (sc-7832, Santa Cruz), anti-Bax (sc-7480, Santa Cruz),
anti-VEGF (sc-7269, Santa Cruz), and anti-hypoxia-inducible
factor-1 a (HIF-1a) (sc-10790, Santa Cruz). Paraffin-embedded
sections were rehydrated by serial immersion in xylene and
ethanol. After rinsing, the endogenous peroxidase was blocked
with 0.3% hydrogen peroxide. The sections were subsequently
incubated with a biotinylated secondary antibody, followed by
incubation with a streptavidin–peroxidase complex (LSABþkit,
Dako, Heverlee, Belgium). The colour reaction was developed
using 3-amino-9-ethylcarbazole substrate (Dako) as chromogen.
Finally, the sections were counterstained with haematoxylin.
Semiquantitative scoring was based on a method modified
after Coppola et al (1998), with a scale ranging from 0 to 9. The
scale was based on scoring of the fraction of positive cells (0:
all cells negative; 1: o33% positive; 2: 33–66% positive; 3: 466%
positive) and the staining intensity (1: weak; 2: moderate; 3:
intense). Both scores were multiplied to a maximum score of 9.
Scoring was performed separately on the tumour core and
peripheral tumour rim.
Microvascular density and diameter
Microvascular density (MVD) was determined with a method
modified after Weidner et al (1991). After incubating 5mm frozen
slices with anti-CD31 antibodies (TLD-3A12, Serotec, Oxford, UK),
the entire tumour section was scanned at low-power (objective,
 4) to identify ‘hot spots’, which are the areas of highest
neovascularisation. Individual microvessels were then counted
under higher power (objective,  40) to obtain a vessel count in a
defined area, and the average vessel count in three hot spots was
taken as the MVD.
Microvascular diameter was measured on digitised CD31-
stained slices (objective,  10). From each rat, five different zones
were analysed and the largest diameter was measured from all
visible microvessels using NIH ImageJ software (version 1.35p,
available from http://rsb.info.nih.gov/ij).
Microvessel fractal dimension
The tumour-associated microvascular network can be considered
as a complex architecture defined not only by the number of
microvessels but also by the degree of branching, tortuosity, and
irregularity. Fractal analysis of two-dimensional histology slides
has been shown to provide additional information on tumour
microvascular complexity (Sabo et al, 2001; Dey, 2005). Whereas
classical geometrical objects are usually associated with integer
values for a dimension (1 for a line, 2 for a square), complex
biological structures are best defined by a fractal dimension that is
a rational number between 1 and 2. The more complex (branched,
tortuous) the microvascular structure, the closer the fractal
dimension is to 2.
From each tumour, digital images were obtained from five
CD31-stained tumour hot spots (objective,  10) and analysed
with ImageJ software. By applying a colour threshold, non-CD31-
stained pixels were removed from the image. The microvessel
fractal dimension (MFD) was calculated using the box-counting
method. The image is divided into increasingly smaller boxes, and
after each step the number of nonempty boxes is counted.
The fractal dimension is calculated as
D ¼ lim
e!0
logNðeÞ
logð1=eÞ
with e the length of a box side and N(e) the smallest number of
boxes required to contain all CD31-stained pixels. In practice, the
limit of a box sized 0 cannot be applied and therefore the MFD was
calculated as the slope of the curve fitted after plotting log N(e) vs
log (1/e). Calculations were performed with the fractal dimension
plugin available in the ImageJ environment.
Statistical analysis
Data are expressed as mean7standard error (s.e.) of the mean,
unless stated otherwise. Differences between two groups of
continuous data were analysed with the Student’s t-test or, when
data distribution was non-Gaussian, with the nonparametric
Mann–Whitney U-test, whereas differences between fractions
were evaluated with the w
2 or Fisher’s exact test. Statistical
significance was assumed when Pp0.05. All calculations and
plotting were performed with SigmaStat software (version 3.11,
Systat Software, Richmond, VA, USA).
RESULTS
Expression of the EPO receptor
All tumours showed expression of the EPO-R on neoplastic cells
and neoplastic endothelium (Figure 2). There was no difference in
expression score between the control and rhEPO-treated animals.
In both groups, however, EPO-R immunoreactivity was signifi-
cantly higher in the tumour core compared to the vascular tumour
rim.
Effects of rhEPO on haematocrit
Haematocrit values were tested before starting the experiment and
on day 8 (immediately before the first MR imaging and
oxygenation measurements). In rhEPO-treated rats, mean haema-
tocrit showed a 25% increase from 50.770.4% before therapy to
62.670.4% on day 8 (Po0.001, Student’s t-test). In the control
group, haematocrit values remained unchanged.
Effects of rhEPO on tumour growth
The present experiment was intended to detect early microvascular
changes after fractionated RT and not to study the effects of rhEPO
on tumour growth or modulation of RT effects on tumour growth.
Administration of rhEPO was therefore started after a tumour
had developed. Tumour volume before RT was 170.2cm
3 in the
control group and 0.9770.11cm
3 in the rhEPO group (P¼0.79,
Erythropoietin and radiotherapy
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sMann–Whitney U-test). After RT, tumour volume was
0.9970.2cm
3 in the control group and 0.9970.16cm
3 in the
rhEPO group (P¼0.99, Mann–Whitney U-test).
Effects of rhEPO on RT-induced tumour microvascular
changes
Pixel-by-pixel kinetic modelling encompassing both the tumour
core and rim was performed with estimation of three micro-
vascular parameters: plasma flow Fp, permeability surface product
PS, and fractional plasma volume Vp.
Results of DCE-MRI microvascular data modelling are shown in
Figure 3. Microvascular plasma flow in the tumour core of control
rats was significantly lower after RT (Po0.001, Student’s t-test).
No significant effect of RT was noted in the tumour rim of control
animals. In rhEPO-treated rats, microvascular flow in the tumour
core was also significantly lower after RT (Po0.001, Student’s
t-test) but unaffected in the tumour rim. The magnitude of the RT
effect on tumour core flow did not differ significantly between
control and rhEPO-treated animals (33 vs 23% decrease, respec-
tively, P¼0.11, Fisher’s exact test).
In control animals, the microvessel PS was significantly lowered
by RT in the tumour rim (Po0.001, Student’s t-test) but not in the
tumour core. In rhEPO-treated animals, however, PS was not
affected by RT.
Fractional plasma volume was significantly lower in both the
tumour core and rim in control animals after RT (Po0.001,
Student’s t-test). In rhEPO-treated animals, however, no signifi-
cant changes in plasma volume were noted after RT.
Effects of rhEPO on tumour pO2 and LDF
Oxygenation and LDF measurements were performed before and
5 days after completion of fractionated RT. Mean pO2 values
in the tumour core and peripheral rim before and after RT in
both groups are shown in Figure 4A and B. Oxygenation was
significantly better in the tumour rim compared with the tumour
core of all animals (data not shown). In the control group, RT
induced a reoxygenation in the tumour core (P¼0.067, Student’s
t-test) but not in the tumour rim (P¼0.36, Student’s t-test). In
the rhEPO group, on the contrary, no significant difference in
oxygenation was observed in the tumour core (P¼0.12, Student’s
t-test), whereas a significant increase in pO2 was observed in the
tumour rim (P¼0.032, Student’s t-test). Both before and after RT,
pO2 values were significantly higher in rhEPO-treated rats in both
regions of the tumour (data not shown).
Mean LDF values (a.u.) are illustrated in Figure 4C. In all
animals, LDF was significantly higher in the tumour rim compared
with the tumour core. In the control group, RT significantly
decreased LBF in the tumour core (P¼0.023, Student’s t-test), but
not in the tumour rim. In the rhEPO group, however, RT did not
influence LDF in either tumour zone. Before RT, LDF measured in
the tumour core was significantly lower in rhEPO-treated animals
(P¼0.014, Student’s t-test) compared with controls, whereas no
significant difference was present in the tumour rim. After RT,
LDF values in both tumour core and rim were not significantly
different between controls and rhEPO-treated animals (data not
shown).
Effects of rhEPO on microvessel density
Mean microvascular density was 12.571.2 in the control group
and 14.371.4 in the rhEPO group (P¼0.35, Student’s t-test).
Within each group, MVD was significantly lower in the tumour
core compared with the tumour rim (12.571.2 vs 7.370.6,
Po0.001 in the control group and 14.371.4 vs 6.670.5,
Po0.001 in the rhEPO group, Student’s t-test).
Effects of rhEPO on MFD and diameter
Microvessel morphology data are illustrated in Figure 5. Micro-
vessel fractal dimension was spatially heterogeneous. In the
tumour core, MFD was significantly lower in rhEPO-treated
animals (P¼0.006, Student’s t-test). In the tumour rim, however,
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sMFD did not differ between controls and rhEPO-treated animals
(P¼0.62, Student’s t-test), Figure 5C.
Overall microvessel diameter (mm) in tumour tissue was
55.972.1 in the control group and 75.472.7 in the rhEPO group,
Po0.001. The increased microvessel diameter in rhEPO-treated
animals was more pronounced in the tumour core (Po0.001,
Student’s t-test) than in the tumour rim (P¼0.07, Student’s t-test),
Figure 5D.
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Bcl-2
Immunohistochemistry data are summarised in Figure 6. Total
VEGF expression score was significantly higher in the control
group (P¼0.048, Mann–Whitney U-test). Within each group, the
difference in VEGF expression in the tumour core vs tumour rim
was not significant.
Total expression of HIF1a did not differ significantly between
both groups (P¼0.78, Mann–Whitney U-test). There was also no
significant difference in expression of Bax (P¼0.21, Mann–Whitney
U-test) or Bcl-2 (P¼0.72, Mann–Whitney U-test) between control
and rhEPO-treated animals. In rhEPO-treated animals, Bcl-2
expression was significantly lower in the tumour core compared
with the tumour rim (P¼0.012, Mann–Whitney U-test).
DISCUSSION
The presence of hypoxia adversely affects radiotherapy response
and prognosis in cancer patients (Varlotto and Stevenson, 2005).
As the oxygen-carrying capacity is mainly determined by the blood
haemoglobin concentration, pharmacological manipulation aiming
to restore or increase haemoglobin levels have received consider-
able interest in cancer patients undergoing RT or chemotherapy.
Erythropoietin is a pleiotropic hormone whose biological role has
recently been shown to extend not only to the hematopoietic
tissues but also to the neuronal and cardiovascular systems, where
it exerts a cytoprotective effect (Maiese et al, 2005). Administration
of exogenous rhEPO not only improved quality of life but also
increased survival in a number of clinical studies in solid tumours
(Munstedt et al, 2004; Rades et al, 2006). On the other hand, EPO
has been shown to exert direct effects on angiogenesis and tumour
growth mediated by presence of the EPO receptor on endothelial
cells and a number of malignant cell types (Jaquet et al, 2002;
Jelkmann and Wagner, 2004). Preclinical studies investigating the
effect of exogenous rhEPO on tumour growth and angiogenesis
are at present inconclusive (Hardee et al, 2005). Similarly, whereas
some preclinical data suggest that rhEPO increases response to RT,
chemotherapy or photodynamic therapy, other studies did not
identify any effects of rhEPO (Stuben et al, 2003; Pinel et al, 2004;
Kirkpatrick et al, 2006). In the clinical setting, the effects of rhEPO
on locoregional control and survival of cancer patients treated with
RT or chemotherapy are a matter of ongoing controversy. In head
and neck cancer patients undergoing RT and randomised to
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survival were significantly worse in the EPO-treated group,
although anemia was corrected in these patients (Henke et al,
2003). Similarly, the Breast Cancer Erythropoietin Trial (BEST)
examining the use of rhEPO in women with metastatic breast cancer
receiving first-line chemotherapy was terminated prematurely owing
to an observed higher mortality in the rhEPO group (Leyland-Jones,
2003). Both trials have, however, been the subject of criticism
concerning study design, conduct, and post-trial analysis.
We aimed to study how rhEPO modulates the early in vivo
effects of RT on colorectal cancer microvasculature. Undoubtedly,
modulation of RT effects is mediated by both increased oxygena-
tion and direct effects of rhEPO on normal and tumour
microvessels. Moreover, solid tumours are characterised by an
important heterogeneity with both well oxygenated and hypoxic
or necrotic regions. Therefore, noninvasive functional imaging was
used that allows differentiating between different tumour regions.
Expression of the EPO-R was present in all tumours and
significantly more pronounced in the hypoxic tumour core. There
is at present no clearly defined relationship between tumour
hypoxia and expression of the EPO receptor by cancer cells.
In head and neck cancer patients, Arcasoy et al found a positive
correlation between tumour hypoxia and EPO-R expression, whereas
others did not observe any correlation in a similar patient cohort
(Arcasoy et al, 2005; Hoogsteen et al, 2005; Winter et al, 2005).
The experiment was not intended to study changes in
macroscopic tumour growth. We analysed rhEPO-mediated
modulation of tumour cell sensitivity to apoptosis. In contrast to
the findings of Batra et al (2003), we did not observe any difference
in expression of apoptotoc or antiapoptotic markers between
rhEPO-treated animals and controls. The spatial distribution of
apoptotic events did, however, differ in rhEPO-treated animals. In
contrast to control animals, Bcl-2 expression in rhEPO-treated
animals was significantly different between tumour rim and core,
suggesting an increased efficacy of RT in the central region of the
tumour by administration of rhEPO.
Dynamic MRI with a macromolecular CA is a validated
technique to provide a comprehensive assessment of tumour
microvascular physiology (Jackson et al, 2005; Preda et al, 2006).
Pharmacokinetic two-compartment modelling of DCE-MRI data
was performed on regions of interest encompassing the tumour
vascular rim and the tumour central core. Microvascular plasma
flow was significantly decreased by RT in the tumour core (but not
in the tumour rim) of both control and rhEPO-treated animals.
In keeping with previous preclinical and clinical findings (Ceelen
et al, 2006), 5 5Gy of RT decreased endothelial permeability (a
surrogate marker for angiogenesis) in the vascular tumour rim of
control animals. In rhEPO-treated animals, however, endothelial
permeability was unaffected by RT. Similarly, whereas the tumour
vascular volume was significantly lower after RT in both the tumour
core and rim of control animals, no changes were present in rhEPO-
treated animals. This difference in response could be explained both
by the previously described direct angiogenic potential of rhEPO
counteracting the effect of RT and by the ability of rhEPO to remodel
microvessels by an increase in diameter, as confirmed by the
microscopy data (cfr infra) (Jaquet et al, 2002; Tovari et al, 2005).
This modulation of RT effects was accompanied by a
significantly lower expression of VEGF in rhEPO-treated animals,
a finding previously reported in colorectal xenografts (Tovari et al,
2005). As no difference in HIF-1a expression was noted, the
difference in VEGF expression is likely to result both from better
oxygenation of the tumour rim and from direct effects of rhEPO on
VEGF expression. Radiotherapy itself has been shown to induce
changes in tumour tissue oxygenation. After a single dose of 20Gy,
Ljungkvist et al (2006) observed a significant decrease in hypoxic
fraction in a murine adenocarcinoma model. We found the
increase in oxygenation after 5 5Gy to be spatially heterogenous.
Interestingly, in rhEPO-treated animals reoxygenation after RT
mainly occurred in the tumour rim, whereas in control animals
reoxygenation of the core was more pronounced. Administration
of rhEPO resulted in significantly better oxygenation in both
tumour regions compared with control animals. This effect is
attributable to an increased blood oxygen carrying capacity and
has been observed in other preclinical models (Pinel et al, 2004).
Erythrocyte flux was measured with the laser Doppler shift
method and, in contrast to the modelled plasma flow, provides
additional information on rheological properties of the micro-
vasculature. In rhEPO-treated animals, RT did not result in a
decrease in LBF, whereas in the central tumour region of control
animals, LBF was reduced by RT. This difference in LBF response
probably reflects the observed difference in microvessel diameter.
In keeping with others (Hardee et al, 2005), we were unable to
demonstrate any effect of rhEPO on angiogenesis, as reflected by
the similar MVD in both groups. Density of microvessels, however,
is only one functional aspect of a tumour microvascular bed.
Aspects such as morphology (tortuosity, branching pattern,
microvessel diameter), maturation, and endothelial wall perme-
ability represent equally important attributes. We found a
significantly larger microvessel diameter in rhEPO-treated rats.
Moreover, the MFD was significantly lower in the central region of
rhEPO-treated rats, suggesting a lower spatial microvessel com-
plexity (Grizzi et al, 2005). These findings confirm the observation
of Tovari et al (2005) that rhEPO can ‘remodel’ tumour
microvessels, although their density seems unaffected. The exact
mechanism likely involves the direct action of rhEPO on the
endothelium rather than indirect effects mediated through changes
in oxygenation, as VEGF expression was significantly lower in
rhEPO-treated animals compared with control animals.
In conclusion, the effects of RT on colorectal tumour micro-
vascular physiology are spatially heterogeneous and modulated by
administration of rhEPO. Treatment with rhEPO prevented
RT-induced changes in microvascular permeability and tumour
vascular volume, accompanied by a larger microvessel diameter
and altered spatial complexity compared with control animals. It
is at present unclear whether this microvascular modulation
increases or counteracts the antitumoural efficacy of RT in this
model. The present experiment does not allow to draw any
conclusion on the effects of rhEPO on radiation response of the
tumour cell population as opposed to the response of tumour
microvessels. However, as rhEPO resulted in an increased
oxygenation of the tumour rim, radiation response of the
clonogens is likely to be increased by rhEPO, as described by
others (Pinel et al, 2004).
Further preclinical experiments will have to elucidate the
multiple molecular effects of rhEPO and the interaction with RT
on tumour cells, neoplastic endothelium, and normal endothelium.
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